Citadel Advisors
ENGN icon

Citadel Advisors’s enGene Therapeutics ENGN Stock Holding History

Citadel Advisors’s Portfolio ENGN Stock Details ENGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$53.3K Buy
+30,800
New +$126K ﹤0.01% 13085

Other funds holding ENGN

FIS
FCPM III Services Naarden, Netherlands $750M AUM 127.27% 1-Year Est. Return
BCM
BML Capital Management Zionsville, Indiana $176M AUM 123.21% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $4.94B AUM 244.43% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $495B AUM 43.24% 1-Year Est. Return
NI
Nextech Invest Zurich, Switzerland $2.11B AUM 413.84% 1-Year Est. Return
ACM
ADAR1 Capital Management Austin, Texas $2.19B AUM 374.99% 1-Year Est. Return
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return
ACA
Acorn Capital Advisors New York $366M AUM 474.6% 1-Year Est. Return
PLC
Peapod Lane Capital Bedford Hills, New York $148M AUM 89.92% 1-Year Est. Return

Citadel Advisors's ENGN Position: Q2 2026 in Review

Citadel Advisors increased its enGene Therapeutics (ENGN) stake by 366% in Q2 2026, buying an estimated $2.3M and bringing the position to 717,686 shares worth $1.24M. The position accounts for ﹤0.01% of the portfolio, ranked #7682.

Citadel Advisors first reported a position in ENGN in Q4 2023 and has held it in 8 quarters since. The position peaked at $13.6M in Q1 2024. 60 funds tracked by Wall St. Rank hold ENGN as of Q2 2026.

  • Citadel Advisors held 717,686 shares of enGene Therapeutics worth $1.24M as of Q2 2026.
  • Citadel Advisors bought 563,744 enGene Therapeutics shares in Q2 2026, an estimated $2.3M.
  • enGene Therapeutics made up ﹤0.01% of Citadel Advisors's portfolio in Q2 2026, its #7682 holding.
  • Citadel Advisors first reported a position in enGene Therapeutics in Q4 2023 and has held it in 8 quarters since.
  • Citadel Advisors's enGene Therapeutics position peaked at $13.6M in Q1 2024.
  • 60 funds tracked by Wall St. Rank held enGene Therapeutics as of Q2 2026.

Based on Citadel Advisors's 13F filing for Q2 2026, filed 14 Aug 2026.